Dallas, TX (PRWEB) April 14, 2014
Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera et al., 2012). Specifically, adult plaque psoriasis is the focus of this report and is defined using the 2013 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code L40.0. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.
Pfizer’s Xeljanz (tofacitinib [formerly known as tasocitinib]) is a Phase III, oral, small-molecule JAK inhibitor for the treatment of PsO. Clinical trials are located worldwide, including in the US, Germany, and Japan. After a turbulent appearance during a FDA committee meeting in May 2012 and submission of additional data in August 2012, tofacitinib was approved for the treatment of RA in November 2012, albeit with a boxed warning. Xeljanz is the most advanced kinase inhibitor in development for PsO and will be a first-in-class product if it successfully launches for PsO.
Complete report is available @ http://www.marketoptimizer.org/xeljanz-psoriasis-forecast-and-market-analysis-to-2022.html .
Reasons to buy
Purchase a copy of this report at http://www.marketoptimizer.org/contacts/purchase?rname=2000 .
Explore more market research reports on Pharmaceuticals at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals.
MarketOptimizer.org (http://www.marketoptimizer.org/ .) is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.